Characteristics of Intracerebral Hemorrhage During Rivaroxaban Treatment
نویسندگان
چکیده
Novel oral anticoagulants (NOACs) reduce incidence of stroke and intracerebral hemorrhage (ICH) in patients with nonvalvular atrial fibrillation. Several studies demonstrated hematoma expansion in patients with ICH occurring during warfarin therapy and poor clinical outcomes. However, information regarding hematoma size, its expansion, and functional and vital outcomes of patients with ICH occurring during NOAC treatment have been limited and remain largely unclear. Cerebral microbleeds (CMBs) are said to be predictive of the occurrence of ICH or ischemic stroke and to increase the risk of warfarin-associated ICH. Furthermore, a considerable interest has been shown in association between CMBs and subsequent ICH in patients treated with NOACs. In the present study, we investigated clinical and neuroradiological characteristics of patients with ICH occurring during NOAC treatment.
منابع مشابه
Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin.
BACKGROUND AND PURPOSE Neuroradiological characteristics and functional outcomes of patients with intracerebral hemorrhage (ICH) during novel oral anticoagulant treatment were not well defined. We examined these in comparison with those during warfarin treatment. METHODS The consecutive 585 patients with ICH admitted from April 2011 through October 2013 were retrospectively studied. Of all, 5...
متن کاملIntracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies.
Little is known about the pathophysiology of intracerebral haemorrhage that occurs during anticoagulant treatment. In observational studies, investigators have reported larger haematoma volumes and worse functional outcome in these patients than in those with intracerebral haemorrhage and a normal coagulation status. The need to prevent extensive haematoma enlargement by rapid reversal of the a...
متن کاملHemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban.
BACKGROUND AND PURPOSE Rivaroxaban has recently been approved for stroke prevention in atrial fibrillation. However, lack of an effective antidote represents a major concern in the event of intracerebral hemorrhage (ICH). The aims of the present study were to establish a murine model of ICH associated with rivaroxaban, and to examine the effectiveness of different hemostatic factors in preventi...
متن کاملRivaroxaban and apixaban reduce hemorrhagic transformation after thrombolysis by protection of neurovascular unit in rat.
BACKGROUND AND PURPOSE This study aimed to assess the risk and benefit of tissue-type plasminogen activator treatment after oral anticoagulation with rivaroxaban or apixaban compared with warfarin or placebo. METHODS Pretreatment with warfarin (0.2 mg/kg per day), rivaroxaban (2 mg/kg per day), apixaban (10 mg/kg per day), or vehicle (0.5% carboxymethyl cellulose sodium salt) was performed fo...
متن کاملComparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
AIM A network meta-analysis of the three new oral anticoagulants was performed from the three trials comparing dabigatran, rivaroxaban and apixaban with warfarin in patients with atrial fibrillation. METHODS Data were extracted of the RE-LY study of dabigatran 110 mg bid and dabigatran 150 mg bid, the ROCKET AF trial of rivaroxaban and the ARISTOTLE trial of apixaban for the composite outcome...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2014